ClinicalTrials.gg
RecruitingNCT06701825TRANSPGxUpdated Sep 11, 2025

Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus

A Phase 4 interventional study of Tacrolimus and Tacrolimus in Kidney Disease, Chronic, Transplant Recipient (Kidney) and Immunosuppression, sponsored by Instituto de Investigación Hospital Universitario La Paz. Recruiting at 1 site in Spain. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Instituto de Investigación Hospital Universitario La Paz · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
114
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Renal Insufficiency, Chronic with a site in Spain — 38 open to participants now, 55 under way, 23 of them phase 3. Renal Insufficiency, Chronic · Spain.

Planned enrollment
106th of 154
114 · median 252
Started
2025
with 12 others
Phase 4
14 of 188
3 open now
Primary completion
2026-10
later than 14 of 54 live
Registered
155th of 188
by date

Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, this one is the 106th largest by planned enrollment of the 154 interventional ones that give a count, is one of 13 that started in 2025, is one of 14 in phase 4, reaches primary completion later than 14 of the 54 other live ones, and was the 155th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

38 of the 188 studies in Renal Insufficiency, Chronic with a site in Spain are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Renal Insufficiency, Chronic with a site in Spain, or all of them as a file.
02

Study summary

This is a phase IV multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective, cost-effective, and feasible within the Spanish National Health System when compared to the current standard of care. This trial is nested within the iPHARMGx master protocol.

Read the detailed description

This is a nation-wide, multicentre, randomised, controlled, and adaptive phase IV clinical trial that aims to assess the effectiveness and cost-effective of pre-emptive pharmacogenetic testing strategies, including those impacted by genetic variants associated with adverse drug reactions (ADRs) or limited efficacy. The clinical trials will evaluate the effective and cost-effective of pre-emptive genotyping by defining a drug-gene-endpoint triad. Study subjects will be pre-emptively genotyped and, if found to have an actionable gene variant, randomly allocated to either a test group where guideline-based treatment modifications will be initiated or a control group that will be managed according to healthcare provider standard of care (SoC). Subsequently, subjects will be prospectively followed at prespecified timepoints. Detailed information on drug-gene-endpoint triads, allocation schemes, and follow-up visits will be provided in each of the subprotocols. A Data Monitoring Committee (DMC), composed of physician experts, will be appointed for each nested trial to review the data on an ongoing basis, ensuring the safety of participants and scientific validity of the study.

03

Conditions studied

  • Kidney Disease, Chronic
  • Transplant Recipient (Kidney)
  • Immunosuppression

Keywords

  • Tacrolimus
  • Kidney transplant
  • Cost-effectiveness
  • Pharmacogenetic
  • Phase IV Clinical Trial
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be willing and able to provide written prior the initiation of any study procedures.
  2. Subject or their legally authorized representative has voluntarily signed the informed consent document.
  3. Participant is on the waiting list for a kidney transplant.
  4. Subject is able and willing to take part and be followed-up for the majority of the study duration, and adhere to the procedures specified in this protocol.
  5. Subjects must be naïve to any genotyping test of the following genes: CYP3A5.

Exclusion criteria

Exclusion Criteria:

  1. Known /allergy reaction to tacrolimus or any of the .
  2. History of renal, heart, and/or liver transplant.
  3. History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere in a relevant manner with the absorption, distribution, metabolism, or excretion of the study treatment, except for renal disease.
  4. Any condition or situation precluding or interfering the compliance with the protocol.
  5. Any condition at medical discretion for which renal transplantation and/or study treatment should not be received.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
114 participants (estimated)

Study arms

  • Active comparator
    Standard of care

    Patients in this control group will receive treatment with any formulation of Tacrolimus authorized and commercialized in Spain. They will be administered tacrolimus according to clinical practice and the drug's product labeling.

    Drug: Tacrolimus

  • Experimental
    Dose adjusted by guidelines

    Participants in this experimental group will receive treatment with any formulation of Tacrolimus authorized and commercialized in Spain. They will be administered the specific dosage of tacrolimus recommended by the Clinical Pharmacogenetics Consortium's genotype guidelines, utilizing the patient's pharmacogenetic information and characteristics.

    Drug: Tacrolimus

Interventions

  • Tacrolimus at the dosage reccomended by the "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing" based on the subjects pharmacogenetic phenotype.

  • Subject allocated to this arm will receive tacrolimus according to clinical practice and the drug's product labelling. These subject will not receive a personalised dose based on their pharmacogenetic phenotype.

06

What researchers measure

Primary outcomes

  1. Tacrolimus concentrations levels

    Number and percentage of patients achieving tacrolimus target plasma concentrations at visit 3. Tacrolimus concentrations levels at day 4 (+/-1d) will be the effectiveness surrogate outcome. It will be considered therapeutic range levels between 7-10 ng/ml.

    Time frame: 4 days

Secondary outcomes

  1. Incremental cost-effectiveness ratio (ICER)

    Cost-effectiveness ratio that divides the differences in costs between both treatments by the difference in effectiveness between both treatments.

    Time frame: Though study completion, on average 18 months

  2. Number and percentage of patients with transplant rejection.

    Transplant rejection will be considered if there is histological confirmation and/or the patient initiates any type of therapy aimed at treating rejection (e.g. corticosteroids).

    Time frame: Though study completion, on average 18 months

  3. Rate of AE associated to treatment.

    All adverse events associated to tacrolimus will be recorded during the study

    Time frame: Though study completion, on average 18 months

  4. Number and percentage of patients achieving tacrolimus target plasma concentrations at visit 4, 5 and 6.

    Time frame: Week 4, 15 and 26

  5. Healthcare expenditure related to predefined events of interest

    Any costs made as a result of an AE

    Time frame: Though study completion, on average 18 months

  6. Incidence of discontinuation or treatment modification

    Incidence of discontinuation or treatment modification due to lack of effective related to the drug of inclusion.

    Time frame: Though study completion, on average 18 months

Other outcomes

  1. Novel prognostic and predictive genetic biomarkers of tacrolimus safety and effectiveness

    All participants DNA sample will be susceptible of deep sequencing analysis assessed trough techniques only available at Nation Centre of Oncological Investigations (CNIO) and genome-wide association studies when applicable

    Time frame: Though study completion, on average 18 months

  2. Identification of new actionable genes/relevant polymorphisms within the predefined population subsets

    Time frame: Though study completion, on average 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — A copy of the database of data collected during the clinical trial will be attached as an appendix to the publication resulting from this clinical trial.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data will be available at the same time as the results will be published, and will be kept available to everyone without any time limit.

Access criteria: Data will be available indefinitely on the publisher's website, as long as it is kept by the Publisher, for anyone who wishes to access the data, for non-commercial purposes.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 15 months after the start.

Of 101 non-industry phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 65. This study's planned 15 months is below that.

Counting every sponsor, half of 117 studies reached it within 43 months; a quarter within 22 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 22, 2024
StartActual
Jun 2, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06701825
Collaborators
Instituto de Salud Carlos III
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Jun 2, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 11, 2025

Study contacts

Alberto M. Borobia, MD, PhD
Contact
alberto.borobia@salud.madrid.org
+34 912071466

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion